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ABSTRACT
Amoxicillin-clavulanate is the most common cause of idiosyncratic drug-induced liver injury 
(DILI). Drug-specific CD4+ T-cells have been detected in patients with DILI, suggestive of an 
immune aetiology. Furthermore, genetic associations including the HLA DRB1*15:01-
DQB1*06:02 haplotype influence susceptibility. Amoxicillin forms protein adducts that are 
postulated to activate T-cells, by conjugating with lysine residues. However, a role for such 
adducts has not been described. This study aimed to (1) investigate whether amoxicillin-
modified HLA-DRB1*15:01-DQB1*06:02 binding peptides selectively activate DILI patient T-
cells and (2) define the nature of the T-cell response with respective to antigen structure. 
Peptides carrying lysine residues for amoxicillin binding in positions (KP) 2-6 and anchors for 
the HLA-DRB1*15:01-DQB1*06:02 haplotype were designed. The amoxicillin-modified 
peptides were characterized by mass spectrometry prior to culturing with patient PBMC. T-
cell clones were then tested for specificity with amoxicillin, unmodified- and amoxicillin-
modified peptides, and structural variants. Amoxicillin-modified KP-2 and KP-3 peptide-
specific CD4+ clones proliferated and secreted IFN-, IL-10, perforin and/or IL-17/IL-22 in a 
dose-dependent manner and displayed no cross-reactivity with amoxicillin, unmodified 
peptide or with positional derivatives. The T-cells response was HLA class II-restricted and the 
amoxicillin-modified peptides bound selectively to HLA-DRB1*15:01 and/or DQB1*06:02.  To 
conclude, we show that amoxicillin-modified peptides bind to both components of the risk 
haplotype to stimulate DILI patient T-cells and describe the importance of the position of 
nucleophilic lysine residue in the HLA binding peptide sequence.
Key words: Drug-induced liver injury, T-lymphocytes, human, antigen
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INTRODUCTION
Idiosyncratic drug-induced liver injury (DILI) is a major health concern resulting in significant 
patient morbidity and mortality. The delayed onset of DILI and the discovery of several 
associations with HLA Class I and Class II alleles in patients provides evidence that liver injury 
may be the result of a delayed-type immunological reaction. Notable examples include the 
association between HLA-B*57:01 and flucloxacillin-induced liver injury where 1 in every 500-
1000 individuals expressing the allele will develop DILI (Daly et al., 2009), and the more 
recently identified associations between the HLA-A*33 serotype and terbinafine-induced liver 
injury (Nicoletti et al., 2017) and HLA-B*14:01 and HLA-B*35:01 and trimethoprim-
sulfamethoxazole-induced liver injury (Li et al., 2020). Amoxicillin-clavulanate, the most 
common cause of idiosyncratic DILI, is associated with the HLA class I allele HLA-A*02:01 and 
the class II haplotype HLA-DRB1*15:01-DQB1*06:02 (Lucena et al., 2011). 
As a result of the genetic association studies, we have investigated whether drug-specific T-
cells are detectable in peripheral blood mononuclear cells (PBMC) from patients with liver 
injury. Flucloxacillin-specific CD8+ T-cells were isolated from PBMC of HLA-B*57:01 positive 
patients and the T-cell proliferative response and cytokine release was restricted to the risk 
allele (Monshi et al., 2013). Furthermore, CD8+ T-cell infiltrates have been identified in HLA-
B*57:01 positive patient liver biopsies (Wuillemin et al., 2014). A mixture of amoxicillin- and 
clavulanic acid-specific CD4+ T-cells have been isolated from PBMC of patients with 
amoxicillin-clavulanate-induced liver injury (Kim et al., 2015). However, using the parent 
drugs (amoxicillin and clavulanic acid) to activate cloned T-cells it was not possible to elucidate 





























































Tailor et al 4
whether the drugs interacted with the HLA risk alleles identified in the genetic studies 
described above. 
Drugs interact with HLA molecules and activate T-cells via two pathways (Meng et al., 2018).  
In the hapten model, a drug must bind covalently to a protein. The protein adduct then 
undergoes processing within antigen presenting cells prior to display of the derived peptides 
on the cell surface within HLA molecules. Alternatively, the pharmacological interactions 
model suggests a drug can interact reversibly with HLA molecules and stimulate T-cells 
directly (Pichler et al., 2011; White et al., 2015; Illing et al., 2016). In amoxicillin-clavulanate 
DILI patients, T-cells are stimulated with antigen presenting cells covalently modified with 
amoxicillin and the stimulation is dampened by inhibiting exogenous and endogenous protein 
processing (Kim et al., 2015; Yaseen et al., 2015). Additionally, multiple amoxicillin-modified 
proteins have been characterised in patient serum (Meng et al., 2016; Ariza et al., 2014). 
These data suggest that amoxicillin stimulates patient T-cells via the hapten model; however, 
there are still many unknown aspects. The exact peptide, group of peptides, or their source 
protein, that activates T-cells have not been identified. Also, whether amoxicillin is covalently-
bound to stimulatory peptides and has any chemical interaction with the T-cell receptor is 
unclear. 
The aims of this study were to (1) utilize mass spectrometric and peptide purification methods 
to synthesize positional derivatives of amoxicillin-modified designer HLA binding peptides, by 
placing lysine on different locations on the peptide backbone and (2) investigate their capacity 
to activate DILI patient T-cells. Peptides with anchor residues for HLA-DR15 and HLA-DQ6 





























































Tailor et al 5
were used to determine whether one or both of the HLA Class II alleles DRB1*15:01 and 
DQB1*06:02 associated with amoxicillin-clavulanate-induced liver injury are involved in the 
presentation of the drug antigen to patient T-cells. 
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MATERIALS AND METHODS
Design of amoxicillin-modified peptides
Amoxicillin-peptides were constructed using anchor residues for DR15 derived from the 
SYFPEITHI database based on HLA peptide elution data (Rammensee et al., 1999). However, 
based on the known anchor residues for DQ6, the peptides would also be tolerated by DQ6 
(Ettinger et al., 1998). Peptides were designed with a poly-alanine backbone 12 amino acids 
in length with the addition of glutamic acid to improve peptide solubility. As I=)
 can 
bind to the peptide n-terminal amino group, peptides were amino acetylated to avoid non-
specific binding. Lysine could be inserted in four locations within the binding motif, therefore, 
four positional derivatives of the peptide were designed (Fig. 1). Peptides were named 
according to the location of the lysine relative to the anchor residue leucine on the peptide 
backbone. For example, KP2 refers to the peptide where lysine is in position 2. Alanine was 
chosen as an inert amino acid to incorporate into the sequence. This enabled clear chemical 
discrimination with locations with a drug-modified lysine to explore the role of drug-
modification and modification position at TCR contact sites. If other amino acids were 
present, then it would have been more difficult to distinguish whether observations were due 
to the drug-modification or some additional binding effect caused by the other amino acids 
present.
Generation of amoxicillin-modified peptides
Peptides were purchased from SYN-Peptide Ltd as per the design specification (Fig. 1). 
Amoxicillin sodium (GlaxoSmithKline, Ware, UK) was incubated with the peptides at a 10:1 
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molar ratio for 24 hours at 37oC in 0.1mM Na2CO3 buffer, adjusted to pH10. Peptide 
modification was confirmed by mass spectrometric analysis following sample clean-up using 
C18 ZipTips according to the manufacturers instructions.
HPLC purification of amoxicillin-modified peptides
Peptides were acidified with 0.1% formic acid and purified using reverse phase HPLC (Agilent 
1200) and a Kinetex C18 (Phenomenex, 2.6µM; 100Å) column with the following gradient 
(min, %B; 0, 2%; 15, 50%; 15.10; 95%; 17, 95%; 17.10, 2%; 28, 2%). The amoxicillin-peptide 
peak was found at a retention time of 14.7 minutes with the amoxicillin-amoxicillin-peptide 
peak at 15.1 minutes (Sup. Fig. 1B). Multiple fractions were collected and dried using an 
Eppendorf concentrator before LC/MS/MS analysis or use in T-cell assays (Sup. Fig. 1C&E).
Mass spectrometric analysis
The free amoxicillin remaining in the amoxicillin-modified peptide fractions were quantified 
by mass spectrometry. Calibration standards were prepared at the following concentrations 
(100, 250, 500, 1000, 2500, 5000nM). All samples were diluted in 0.1% formic acid prior to 
analysis and spiked with the internal standard ampicillin (5µM). Samples and standards were 
analysed immediately by a QTRAP 4000 mass spectrometer (AB Sciex,) coupled with an 
Ultimate 3000 LC system (Dionex Corporation, Sunnyvale, CA). The multiple reaction 
monitoring transitions for each analyte were as following: amoxicillin 366.2/159.9 and 
366.2/349.0, and ampicillin 350.2/160.2. Other MS parameters, such as voltage potential and 
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collision energy were optimised to achieve great sensitivity. Data acquisition and 
quantification were performed using Analyst 1.5 software.
 
Mass spectrometric characterisation of the un-purified peptides identified three major peaks 
including unmodified peptide, amoxicillin-modified peptide and the amoxicillin-amoxicillin 
(dimer)-peptide (Sup.Fig1G). Unmodified peptides and the modified peptides were 
characterised using previously described methods on a TripleTOF 5600 (AB Sciex) mass 
spectrometer (Jenkins et al., 2013). Briefly, samples were delivered into the mass 
spectrometer by automated in-line reversed phase liquid chromatography, using an Eksigent 
NanoUltra cHiPLC System (AB Sciex) mounted with a trap and analytical column (15 cm × 75 
RA packed with ChromXP &GS&- 3 R$ A NanoSpray III source was fitted with a 10 R inner 
diameter PicoTip emitter (New Objective). Samples were loaded in 0.1% formic acid onto the 
trap, which was then washed with 2% acetonitrile/0.1% formic acid for 10 min at 2 R-E 
before switching in-line with the analytical column. A gradient of >S9BN (v/v) 
acetonitrile/0.1% (v/v) formic acid over 90 min was applied to the column at a flow rate of 
300 nL/min. Spectra were acquired automatically in positive ion mode using information-
dependent acquisition, using mass ranges of 8BBS.BB Da in MS and BBS8BB Da in MS/MS. 
Up to 25 MS/MS spectra were acquired per cycle (approximately 10 Hz) using a threshold of 
100 counts per s, with dynamic exclusion for 12 s and rolling collision energy. Modified 
peptides were identified by filtering for specific fragment ions in PeakView 1.2.0.3 (AB Sciex) 
and manual inspection of the spectra. Positional derivatives had an equal mass, therefore key 
fragment ions are highlighted to distinguish their sequences (Sup. Figs. 3-6). 
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Human subjects
Patients  with amoxicillin-clavulanate-induced liver injury were enrolled from the DILIGEN 
study (Lucena et al., 2011) with the clinical characteristics of hepatocellular / mixed type 
injury. Chemagic magnetic separation (Chemagen, Baesweiler, Germany) was used to extract 
genomic DNA followed by high-resolution HLA-typing carried out by the Histogenetics 
Laboratory (Histogenetics, Ossining, NY). The HLA type and demographics of the patients have 
been described previously (6). One patient expressed the HLA-DRB1*15:01, HLA-DQB1*06:02 
haplotype (HLA-A*02:01/03:01, HLA B*07:02/57:01, HLA-DRB1*15:01/07:01, HLA-
DQB1*03:03/06:02, HLA-DQA1*01:02/02:01) and PBMC from this patient were used to 
generate clones to explore the immunogenicity of the amoxicillin-modified peptides.
Healthy donors positive or negative for the risk haplotype or expressing either HLA-
DRB1*15:01 or HLA-DQB1*06:02 were also recruited to the study to generate Epstein-Barr 
virus (EBV)-transformed B-cells as antigen presenting cells for HLA allele restriction studies. 
The HLA genotype of the donors is shown in Sup. Table 1. Approval for the study was acquired 
from the Liverpool local research ethics committee and informed written consent was 
obtained from each donor. 
Generation of T-cell clones and EBV-transformed B-cell lines 
PBMC (106 cells/well; 0.5ml) were cultured with amoxicillin (1.5mM; 0.5ml) or amoxicillin-
modified peptides (100µM; 0.5ml) in RPMI 1640 supplemented with 10% human AB serum 
(Class A; Innovative Research Inc., Novi, MI), 10mM of L-glutamine, 25mM of HEPES and 25 
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µg/mL of transferrin (Sigma-Aldrich, Gillingham, UK). PBMCs were fed with media containing 
human interleukin (IL)-2 (PeproTech, London, UK) added on days 6 and 9. On day 13, cells 
were seeded into 96 well plates as described in previous studies (Wu et al., 2007). EBV-
transformed B-cell lines were generated by transforming PBMC with supernatant from the 
EBV-producing cell line B95.8. EBV-transformed B-cell lines were maintained in RPMI 1640 
supplemented with 10% fetal bovine serum (Invitrogen, Paisley, UK), 100mM L-glutamine, 
penicillin and streptomycin (Sigma-Aldrich, Gillingham, UK). 
Antigen specificity of the clones was assayed by culturing T-cells (5x104 cells/well, 50µL) with 
autologous EBV-transformed B-cells lines (1x104 cells/well, 50µL) and amoxicillin (1.5mM; 
100µL) or amoxicillin-modified peptides (5µM; 100µL). Proliferation was assessed by the 
addition of [3H]-thymidine (0.5 µCi/well, 5 Ci/mmol; Morovek Biochemicals, Brea, CA) for the 
last 16 hours of the culture period. Incorporated radioactivity was measured by scintillation 
counting. Clones with a stimulation index greater than 2 were expanded using a stimulation 
cocktail made with T-cell culture media containing IL-2 (200I IU/ml) PHA (5µg/ml) and 
irradiated allogeneic PBMCs (5x105). T-cell clones were maintained through the addition of 
IL-2 (200I IU/ml) every two days until further experiments were carried out.
T-cell specificity assays
T-cell clones were subjected to a further test to confirm specificity to amoxicillin-modified 
peptides in comparison to unmodified peptides. This and all subsequent T-cell assays 
underwent the same co-culture procedure; clones (5x104 cells/well) were cultured with or 





























































Tailor et al 11
without autologous irradiated EBV-transformed B-cells as the antigen presenting cell (1x104 
cells/well) in the presence of amoxicillin-modified peptides (25-50µM) and unmodified 
peptides (up to 500µM). Proliferation and cytokine secretion were measured using [3H]-
thymidine incorporation and the Enzyme Linked ImmunoSpot Assay (ELISpot  2"=X IL-13, 
IL-5, perforin, IL-22, IL-17, IL-10, granzyme B), performed according to the manufacturers 
instructions (Mabtech, Nacka Strand, Sweden). CD4+/CD8+ and chemokine receptor (CCR 1-
6 & 8-10, CXCR 3, CD69, E-CAD and CLA) phenotyping was performed using flow cytometry 
(BD FACs Canto II) by staining with fluorescent antibodies (R&D Biosystems). Due to limited 
quantities of the modified peptides, the concentration used in subsequent mechanistic 
studies was 10µM, the lowest concentration required to gain a significant response in all 
clones. This was determined by titrating the concentration of the amoxicillin-modified 
peptides (0.01  10µM) and analysis of proliferation. Only CD4+ T-cells were taken for further 
assessment.
Cross-Reactivity studies
In initial experiments clones responsive towards a specific amoxicillin-modified peptide and 
irradiated EBV-transformed B-cells were cultured with the other positional derivative 
peptides (with and without amoxicillin modification) and proliferation was measured by 
[3H]thymidine incorporation. Subsequently, a number of peptide reagents were generated 
using the same synthesis, purification and characterization processes as the amoxicillin-
modified peptides and used to characterize T-cell cross-reactivity in proliferation or cytokine 
release assays. These included ampicillin-modified-KP2 peptide, amoxicillin-modified HSA 
peptide K204 and several amoxicillin dimer-modified peptides. Furthermore, HLA binding 





























































Tailor et al 12
inhibition was performed by culturing increasing concentrations (10-300µM) of unmodified 
peptides with the amoxicillin-modified peptides (10µM) prior to analysis of proliferation and 
cytokine release. 
HLA-restriction studies
HLA class I and HLA class II (including HLA class II DR and DQ subtypes) blocking antibodies 
(and isotype controls; BD Biosciences, Oxford, UK) were incubated with EBV-transformed B-
cells and T-cell clones 30min prior to addition of amoxicillin-modified peptides and analysis of 
proliferation and/or IFN- release by ELIspot. To test which specific HLA molecules the 
amoxicillin-modified peptides interact with prior to activating T-cells,  the HLA-typed 
Liverpool Healthy Volunteer Cohort was accessed and donors were selected based on the 
presence or absence of specific co-amoxiclav HLA risk alleles (HLA-DRB1*15:01 and/or HLA-
DQB1*06:02). EBV-transformed B-cell lines were generated from frozen PBMCs, irradiated, 
and used in proliferation assays with the amoxicillin-modified peptides and T-cell clones.
Toxicity Assay
The toxicity of the drug-modified peptides was tested by incubating freshly isolated PBMC 
(1.5x106; 200µl) from healthy volunteers for 4 days after which PHA (5µg/ml) was added and 
proliferation measured using [3H]-thymidine. Toxicity was measured as an inhibition of 
proliferative activity observed with cultures in the absence of peptide upon stimulation with 
PHA.
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RESULTS
Characterization of amoxicillin-modified peptides
Amoxicillin-modified peptides (KP2-6, with the number referring to the position of the drug-
modified lysine with respect to the leucine anchor residue [Fig. 1]) were successfully 
generated, purified and characterized using mass spectrometry. Although the mass of each 
peptide was the same, key fragment ions derived from the cleavage of the peptide backbone 
were identified for each modified peptide to distinguish positional derivatives and the 
amoxicillin peak. Ions which represent amino acids with the mass addition of amoxicillin are 
highlighted for each amoxicillin-modified peptide (Sup. Figs. 3-6). 
Each batch of peptides generated was analysed to quantify unbound amoxicillin. The 
amoxicillin-modified peptides were found to contain approximately 2-3% unbound 
amoxicillin correlating to 1.5µM amoxicillin with the highest concentration of amoxicillin-
modified peptide used in T-cell assays (Sup. Fig. 2). To put this into perspective for the range 
of amoxicillin-modified peptide concentrations used in this study: 100µM amoxicillin-
modified peptide contained 3.21 ± 0.4 µM free amoxicillin; 25µM amoxicillin-modified 
peptide contained 0.8 ± 0.1 µM amoxicillin; and 10µM, the concentration most frequently 
used in T-cell assays, contained 0.32µM ± 0.04 µM amoxicillin remaining. This was well below 
the concentration of amoxicillin which we have previously shown could activate T-cells (8µM). 
The amoxicillin-modified and unmodified peptides subjected to the same extraction and 
purification protocols were assayed for direct toxicity towards PBMC. No direct PBMC toxicity 
was observed with the amoxicillin-modified-peptide concentrations used to stimulate T-cells 
(0.3-300 µM) (Sup. Fig. 2). 
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Generation of amoxicillin-modified peptide-specific CD4+ T-cell clones
T-cell cloning was performed following antigen-driven T-cell enrichment by treating PBMC 
with the amoxicillin-modified peptides (KP2-6) for 13-14 days. Individual T-cells were serially 
diluted and expanded with repeated mitogen stimulation. T-cell colonies reaching 
approximately 0.5-1.0x106 cells were assessed for antigen-specific proliferation. In total, over 
900 colonies were tested for reactivity against the amoxicillin-modified peptides; colonies 
with a stimulation index (SI) greater than 2 were deemed potentially responsive and were 
expanded for further testing. 
Clones were initially tested using a relatively low concentration of 5µM amoxicillin-modified 
peptide. Cloning with amoxicillin-modified peptides-KP2 and KP3 identified 5/240 colonies 
from each serial dilution with an SI>2 (Fig 2A & B). Of these, four CD4+ (Fig. 2C) T-cell clones 
displayed strong proliferative responses and cytokine release @2"=X and IL-13) in response to 
the amoxicillin-modified peptides tested at 25-50 µM (50 µM; SI Range = 12-25, P<0.005) (Fig. 
2D,E). Amoxicillin-modified peptide-KP3 clones 35 and 90 showed low levels of reactivity with 
the unmodified KP3 peptide, though, at much higher concentrations (500µM). In contrast 
amoxicillin-modified-KP2 peptide-responsive clones were not activated with the unmodified 
peptide. Dose titration of amoxicillin-modified peptides demonstrated proliferative 
responses at concentrations as low as 1-10 µM (Fig. 3A) and 2"=X secretion at 0.1 µM (Fig. 
3B). In addition to IFN-, all clones secreted the cytolytic molecule perforin, IL-10 and IL-22 
following antigen treatment and expressed the chemokine receptors CCR4 and CXCR3 (Sup. 
Fig. 7). The amoxicillin-modified-KP3 clones also secreted IL-17. 
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Amoxicillin-modified-KP2 and KP3 responsive clones were assessed for reactivity with 
unmodified or modified positional derivatives, HSA and amoxicillin-modified HSA. Clones KP2-
63, KP2-91 and KP3-35 were stimulated to proliferate with amoxicillin-modified-KP2 or KP3, 
but they did not cross-react with the other peptides, proteins or free amoxicillin. Amoxicillin-
modified KP3-90 clone proliferated readily in the presence of amoxicillin-modified KP3 and 
weakly with unmodified KP3, unmodified KP6 and amoxicillin-modified-KP6 (Fig. 4). 
Cloning to amoxicillin-modified-KP5 and KP6 resulted in 0/208 and 2/216 colonies (Fig. 5A 
and B). On repeated testing, a single amoxicillin-modified-KP6 clone, was found to proliferate 
strongly (50µM; SI=7.4; P=0.0005) in a dose-dependent manner and secrete 2"=X and IL-13 
(Fig. 5C, D). Proliferative responses and cytokine release were not observed with unmodified 
KP6, amoxicillin-modified or unmodified positional derivatives, amoxicillin-modified-HSA or 
the free drug (Fig. 5D). Interestingly, the clone expressed CD8+ and was therefore not 
interacting with the DR15-DQ6 haplotype. Therefore, no further investigation was performed 
on this amoxicillin-modified peptide-specific clone.
Structural features of the amoxicillin-modified-KP2 and KP3 peptide-specific T-cell response
The structural features of the amoxicillin-modified-KP2 and KP3 peptide-specific T-cell 
response was further investigated in a series of mechanistic studies. First, amoxicillin dimer-
KP2 and KP3 peptides were characterised, purified and incorporated into the T-cell assay. In 
these peptides, the lysine residue was modified with a dimerized amoxicillin moiety (Sup. Fig. 





























































Tailor et al 16
8). This was deemed important as the dimerized adduct has been identified in patient serum 
(Meng et al., 2016). Amoxicillin-modified-KP2 and KP3 clones were stimulated to proliferate 
in the presence of peptides modified with amoxicillin and the amoxicillin dimer (Fig. 6A). 
Secondly, amoxicillin-modified-KP2 and -KP3 peptide-responsive clones were incubated with 
free drug and 100µM of the unmodified peptide to determine whether the peptide conjugate 
is formed in sufficient quantities under cell culture conditions to activate T-cells. T-cell 
proliferative responses were not detected (results not shown).  Thirdly, T-cell stimulatory 
amoxicillin-modified-KP2 and KP3 peptides (10µM) were co-incubated with increasing 
concentrations of unmodified peptide in an HLA binding competition assay. With an increase 
in unmodified peptide, the response to modified peptide was significantly dampened with a 
4.25-fold (P=0.0046) decrease in amoxicillin-modified-KP2 clones at high concentrations of 
unmodified KP2. Amoxicillin-modified-KP3 clone 90 showed cross-reactivity with the 
unmodified KP3 and therefore, the proliferative response was only dampened by 2.1-fold 
(P=0.0067) in the presence of 100µM unmodified peptide. Furthermore, the proliferative 
response began to increase with higher concentrations (200µM) of the unmodified peptide 
(Fig. 6B). 
Previous studies have shown strong reactivity of amoxicillin-specific T-cell clones with the 
structurally similar the I=)
 antibiotic ampicillin at the same drug concentrations (Kim et 
al., 2015). Therefore, fourthly, ampicillin-modified-KP2 was generated, purified and 
characterised (Sup. Fig. 9), no cross reactivity was observed even at 10-fold higher 
concentrations of ampicillin-modified KP2 peptide (Fig. 6C). Finally, an experiment was 
designed to explore whether a peptide derived from HSA containing a similar HLA-





























































Tailor et al 17
DRB1*15:01-DQB1*06:02 binding motif, and amoxicillin in the same position, could cross-
react with the amoxicillin-modified-KP3 clones. Amoxicillin-modified HSAK204 chosen for its 
similarity with the KP3 peptide, was synthesized, characterised and purified (Sup. Fig. 10). The 
amoxicillin-modified-KP3 clones were not stimulated to proliferate in the presence of titrated 
concentrations of the amoxicillin-modified-HSAK204 peptide (Fig. 6D).
Assessment of HLA Restriction
Anti-MHC class I and II blocking antibody experiments revealed that activation of amoxicillin-
modified-KP2 and -KP3-responsive clones was class II restricted (Fig. 7). While the peptides 
were designed to bind DRB1*15:01, the anchor amino acids could also be accommodated by 
the other component of the amoxicillin-clavulanate haplotype DQB1*06:02. Thus, to 
characterize the HLA molecules that the peptides were interacting with to activate the clones, 
EBV-transformed B-cells were generated from 6 healthy donors: 3 expressing the HLA risk 
haplotype and 3 expressing other HLA -DR and -DQ alleles. Strong proliferative responses 
were observed when clones (amoxicillin-modified-KP2 and -KP3 responsive) were incubated 
with the amoxicillin-modified peptides and autologous antigen presenting cells or antigen 
presenting cells from the donors expressing HLA-DRB1*15:01-DQB1*06:02. In contrast, the 
strength of the proliferative response with antigen presenting cells from donors negative for 
the HLA risk haplotype was similar to that observed in the absence of antigen presenting cells 
(Fig. 8A). 
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To determine whether the peptides were interacting with HLA-DRB1*15:01 and/or HLA-
DQB1*06:02 antigen presenting cells were generated from donors positive for HLA-
DRB1*15:01 but negative for HLA-DQB1*06:02 and vice versa. Amoxicillin-modified-KP2 
peptide-responsive clones showed strong reactivity with peptide and antigen presenting cells 
expressing either risk allele. In contrast, amoxicillin-modified-KP3 peptide-responsive clones 
showed strong proliferative responses to the peptide only in the presence of antigen 
presenting cells from donors expressing DQB1*06:02 (Fig. 8B). Blocking experiments with 
anti-HLA-DR and DQ antibodies confirmed activation of clones with amoxicillin-modified KP3 
peptide was restricted to HLA-DQ (Sup. Fig. 11). 
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DISCUSSION
Amoxicillin-clavulanate is the most common cause of idiosyncratic DILI in the USA and Europe 
and hence the most important form of DILI to study (Andrade et al., 2005; Chalasani et al., 
2008). Pharmacogenomic investigations have reported a significant association between the 
HLA class II haplotype DRB1*15:01-DQB1*06:02 and susceptibility to amoxicillin-clavulante-
induced DILI (Hautekeete et al., 1999; ODonohue et al., 2000; Donaldson et al., 2010; 
Andrade et al., 2004). Furthermore, we have isolated and characterized amoxicillin- and 
clavulanic acid-responsive T-cells, from patients with DILI, in terms of phenotype and function 
(Kim et al., 2015; Yaseen et al., 2015). However, unlike our previous study of flucloxacillin-
induced DILI in patients expressing HLA-B*57:01 (Monshi et al., 2013), we were not able to 
show that either amoxicillin or clavulanic acid interact with HLA-DRB1*15:01 or HLA-
DQB1*06:02 to activate CD4+ T-cells. In fact, to date, it has not been possible to link HLA class 
II genetic associations to the activation of T-cells and the iatrogenic disease for any form of 
DILI. Thus, the objective of this study was to utilize fully-characterized drug-modified 
peptides, instead of the parent drug, as a source of antigen to probe T-cell responses and to 
investigate whether the peptides bind with a degree of selectivity to components of the 
amoxicillin-clavulante HLA class II haplotype to stimulate T-cells. We present evidence that 
amoxicillin-modified peptides bind to both HLA-DRB1*15:01 and HLA-DQB1*06:02 to 
stimulate DILI patient T-cells and describe in detail the importance of the position of 
nucleophilic lysine residue that amoxicillin modifies in the HLA binding peptide sequence.
The approach that we used derives from an early study by Weltzein and colleagues who 
synthesized benzylpenicillin-modified peptides containing anchor residues that interact with 
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the HLA class II binding cleft with the addition of a lysine residue to bind the drug. Multiple 
positional derivatives of these peptides were designed by placing lysine on different locations 
on the peptide backbone (Padovan et al., 1997). Importantly, our peptide sequences were 
designed with the help of the SYFPEITHI database to contain anchor residues for both HLA-
BRB1*15:01 and HLA-DQB1*06:02. In total, 4 peptides were used to synthesize amoxicillin 
and amoxicillin dimer adducts. Lysine residues for amoxicillin modification were located in 
positions 2,3, 5 and 6 with respect to the leucine anchor (Fig. 1). 
Amoxicillin-modified-KP2 and KP3 CD4+ clones isolated from the patient with liver injury 
were stimulated to proliferate and secrete IFN- in a dose-dependent manner in the presence 
of the modified peptides. Interestingly, position 2 and 3 have been proposed as critical T-cell 
receptor contact sites in previous studies exploring the immunogenicity of myelin basic 
protein-derived peptides in HLA-DRB1*15:01+ patients with multiple sclerosis 
(Wucherpfennig et al., 1994). Amoxicillin-modified-KP2 peptide-responsive clones were not 
activated with the unmodified peptide, whereas very low levels of proliferation and IFN- 
release were observed with the amoxicillin-modified-KP3 peptide-responsive clones. 
Therefore, the carrier peptide must form part of the antigenic determinant for certain clones. 
The hapten could sit above the HLA binding peptide when interacting with T-cell receptors or 
alternatively be accommodated in a pocket of the HLA binding groove where it would induce 
steric stress and the possible presentation of peptides in an unnatural conformation. The 
dimerized amoxicillin-modified peptide proved a useful tool to investigate the HLA binding 
interaction as it is unlikely that the large drug structure (approximately the size of 5 amino 
acids) could be accommodated in an HLA pocket. As the dimerized peptide adduct stimulated 





























































Tailor et al 21
all amoxicillin-modified peptide-responsive clones to proliferate it is probable that the drug 
component of the amoxicillin-modified peptide protrudes from the HLA molecule and faces 
the T-cell receptor. Collectively, these data confirm that drug hapten modification of peptides 
generates novel antigenic determinants for T-cells as described originally by Padovan et al 
(1997) and more recently by Azoury et al (Azoury et al., 2018) with benzyl penicillin. However, 
they also generate the concept that hapten modification enhances the intrinsic 
immunogenicity of endogenous peptides.  
CD4+ clones reactive towards amoxicillin-modfiied-KP5 and KP6 peptides were not detected. 
However, one CD8+ clone was stimulated with the drug-modified-KP6 peptide. These data 
raise the intriguing possibility that drug-modified HLA class II binding peptides also activate 
CD8+ cells in a truncated or spliced form following antigen processing through modification 
of HLA class I molecules. Furthermore, the patient is also positive for HLA-A*0201, which is 
part of the wider risk haplotype. It is plausible that this peptide, could be presenting via this 
allele. It would be interesting to study the structure of the peptide that activates CD8+ T-cells; 
however, this was beyond the scope of the current investigations.  
Cross-reactivity studies were performed to explore the nature of the antigenic epitope that 
interacts with the CD4+ T-cells. Interestingly, none of the amoxicillin-modified peptide-
responsive clones were activated with soluble amoxicillin. This differed from the observations 
of Padovan et al using T-cells from benzylpenicillin allergic patients where drug-modified 
peptide-specific T-cells were also activated with the free drug (Padovan et al., 1997). Peptide 
sequences chosen for this study were synthetic using a simple alanine backbone, an 
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amoxicillin-modifiable lysine residue and relevant anchor amino acids to mimic the HLA 
binding interaction of multiple natural peptides to allow us to detect as many amoxicillin-
modified peptide-specific T-cells as possible. We did synthesize a natural amoxicillin-modified 
HSA-derived HLA binding peptide with similar anchor residues to our designer KP3 peptide. 
However, this peptide did not activate the clones. Thus, in on-going experiments we are 
beginning to elute the thousands of HLA class II bound peptides from amoxicillin-treated 
antigen presenting cells to characterize the drug-modified and unmodified 
immunopeptidome. These studies will allow us to identify natural amoxicillin-modified HLA 
class II binding peptides for a more detailed assessment of T-cell reactivity. 
The lack of cross-reactivity between amoxicillin-modified-KP2 peptide-responsive and 
amoxicillin-modified-KP3 peptide-responsive clones indicate that T-cell activation is highly 
specific with respect to the drug position within the HLA peptide binding groove. Furthermore 
the replacement of amoxicillin with ampicillin in the KP2 peptide did not activate the clones. 
The only difference in the structures of ampicillin and amoxicillin is a single hydroxyl group.
HLA-restriction studies were conducted to investigate the role of the risk haplotype in the 
CD4+ T-cell response to the amoxicillin-modified peptides. All clones were activated with the 
amoxicillin-modified peptides in the presence of antigen presenting cells expressing the risk 
haplotype, whereas with donors expressing other HLA-DRB1 and -DQB1 alleles, the strength 
of the proliferative response was similar to that seen in the absence of antigen presenting 
cells. Moreover, using antigen presenting cells expressing only one component of the HLA risk 
haplotype and HLA class II sub-type blocking experiments, we demonstrated that clones 
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responsive towards amoxicillin-modfiied-KP2 peptide may be activated through an 
interaction with DQB1*06:02 as well as DRB1*1501, while clones responsive towards 
amoxicillin-modfiied-KP3 peptide require a selective interaction with DQB1*06:02. HLA allele 
restriction was not observed in previous experiments with CD4+ T-cell clones responsive 
toward soluble amoxicillin (Kim et al., 2015; Yaseen et al., 2015). This difference presumably 
relates to the high milli-molar concentrations of amoxicillin used to activate T-cells, which will 
either saturate the binding cleft of multiple HLA class II molecules and/or modify numerous 
proteins that contain peptide sequences for multiple HLA class II molecules. Unfortunately, 
patients and volunteers were not screened for the DRB5 allele, of which DRB5*01:01 is also 
a known component of the wider risk haplotype. While it is plausible these peptides may also 
be able to interact with this allele, reports have demonstrated a low degree of overlap in the 
peptide repertoires for DRB1*15:01 and DRB5*01:01 (Scholz et al., 2017). However, this 
would be an area of interest for future studies to better understand the risk haplotype.
HLA is thought to be one of factors influencing susceptibility to DILI, and while certain patients 
are carriers of the HLA risk allele(s), many carriers of the allele(s) will not have liver injury and 
there will be some who have liver injury but are not carriers of the allele(s). T-cell activation 
and differentiation is highly influenced by regulatory pathways involving receptor ligand 
interactions (e.g., PD-1, CTLA-4), Tregs and cytokines with certain cytokines providing a shift 
towards certain cellular phenotypes. An analysis of the secretory molecules release by the 
amoxicillin-modified peptide-responsive CD4+ clones identified the cytolytic molecule 
perforin and alongside the regulatory cytokine IL-10. While it is atypical for CD4+ clones to 
have cytolytic properties, aberrant expression of MHC Class II on hepatocytes has been 
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observed in the context of autoimmune disease (Herkel et al., 2003). As such, it is plausible 
that this could provide some clinical relevance for a CD4 mediated process for hepatotoxicity 
and a reason for the class II association. The analysis of MHC class II expression in liver biopsies 
from hypersensitive patients would be an interesting avenue of further study.  Furthermore, 
amoxicillin-modified-KP2 responsive cells were IL-22 positive and IL-17 negative, which 
alludes to a Th22 phenotype, while the amoxicillin-modified-KP3 responsive cells were IL-22 
positive and IL-17 positive indicative of a Th17 phenotype. IL-17 induces an inflammatory 
response while IL-22 may be involved in regeneration (Eyerich et al., 2010). An analysis of cell 
surface chemokine receptor expression shows a similar profile between the clones with an 
upregulation of CCR4 which is involved in allergic inflammation and also CXCR3 which is 
expressed in response to an adaptive immune response. CXCR3 is also a key receptor 
upregulated in the liver (Oo et al., 2010). Ultimately, it would be interesting to see the role 
that these cells play in the wider context of drug allergy adding to the growing list of aberrant 
T-cell responses observed.
To summarize, our data provide proof-of-concept evidence that drug haptenated peptides 
bind selectively to HLA class II risk alleles associated with a clinically relevant form of 
idiosyncratic DILI to activate CD4+ patient T-cells. Furthermore, we have defined the nature 
of the T-cell response with respect to drug structure and the position of the hapten 
modification on the HLA binding peptide. While our designer peptides are not derived from 
natural proteins they represent an important tool to identify antigenic determinants and 
ultimately define drug-peptide toxicophores involved in the patient T-cell response. Also, 
the availability of powerful bioinformatics tools such as PROSITE, can help match these 
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toxicophores to natural proteins which contain these epitopes. Now that it has been 
established that amoxicillin-modified HLA-DRB1*15:01-DQB1*06:02 binding peptides 
activate T-cells, further structural analyses that are ongoing will help elucidate the nature of 
the receptor binding interaction. Furthermore, HLA class II tetramers incorporating the 
amoxicillin-modified peptide sequences are being developed for flow cytometry-based assays 
to quantify antigen-specific T-cell numbers in naïve, tolerant and hypersensitive patients and 
for the rapid diagnosis of this drug-specific iatrogenic disease. 
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FIGURE LEGENDS
Figure 1. Sequences of amoxicillin-modified HLA-binding peptides. (A) Criteria for the design 
and construct of drug-modified peptides. (B) Sequences of four drug-modified peptides with 
lysine in different locations called positional derivatives. Amoxicillin-modified peptides were 
named according to the location of lysine.  Anchor residues were derived from the SYFPEITHI 
database.
E A A L K A F A A I A EAc
Lysine residue binds I-lactams. The lysine can be placed 
at different locations on the peptide backbone.
12-mer peptide length 
for class II binding 
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Figure 2. CD4+ T-cell clones responsive towards amoxicillin-modified KP2 & KP3 peptides. 
PBMC were cultured individually with the peptides for 14 days prior to cloning by serial 
dilution and repetitive mitogen stimulation. Proliferation of T-cell clones with (A) amoxicillin-
modified KP2 or (B) amoxicillin KP3 peptides and irradiated autologous EBV-transformed B-
cells as antigen presenting cells. This initial experiment was conducted in duplicate. 
Proliferative responses were measured using [3H]thymidine and recorded as a stimulation 
index (proliferation in test incubations with drug/ proliferation in control incubations with 
medium alone) and SI > 1.5 deemed a positive response. (C) Phenotype characterisation of 
amoxicillin-modified peptide-specific clones using flow cytometry. (D) Proliferation of 
amoxicillin-modified KP2 and KP3 peptide specific T-cell clones with amoxicillin-modified and 
unmodified KP2 and KP3 peptides. Clones were incubated with modified or unmodified 
peptides and irradiated autologous antigen presenting cells for 48h. Proliferative responses 
were measured using [3H]thymidine and recorded as mean ± SD cpm of triplicate cultures. (E) 
IFN- and IL-13 cytokine secretion from amoxicillin-modified peptide-specific T-cell clones. 
Clones were incubated with amoxicillin-modified or unmodified peptides and cytokine 
secretion was visualized using ELIspot. 
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Figure 4. Cross reactivity of amoxicillin-modified KP2 and KP3 responsive CD4+ T-cell clones.  
Clones were incubated with modified or unmodified KP2-6 peptides, amoxicillin, HSA or 
amoxicillin-modified HSA  and irradiated autologous antigen presenting cells for 48h. 
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Figure 5. CD8+ T-cell clone responsive towards amoxicillin-modified KP6 peptide. PBMC 
were cultured individually with the amoxicillin-modified KP5 and KP6 peptides for 14 days 
prior to cloning by serial dilution and repetitive mitogen stimulation. Proliferation of T-cell 
clones with (A) amoxicillin-modified KP5 or (B) amoxicillin KP6 peptides and irradiated 
autologous EBV-transformed B-cells as antigen presenting cells. This initial experiment was 
conducted in duplicate. Proliferative responses were measured using [3H]thymidine and 
recorded as a stimulation index (proliferation in test incubations with drug/ proliferation in 
control incubations with medium alone) and SI > 1.5 deemed a positive response. (C) 
Proliferation of amoxicillin-modified KP6 peptide-specific T-cell clone with amoxicillin-
modified and unmodified KP6 peptide. Clones were incubated with modified or unmodified 
peptides and irradiated autologous antigen presenting cells for 48h. Proliferative responses 
were measured using [3H]thymidine and recorded as mean ± SD cpm of triplicate cultures. (D) 
IFN- and IL-13 cytokine secretion from the amoxicillin-modified peptide-specific T-cell clone. 
Clones were incubated with amoxicillin-modified or unmodified peptides and cytokine 
secretion was visualized using ELIspot. 
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Figure 6. Structural features of the amoxicillin-modified-KP2 and KP3 peptide-specific CD4+ 
T-cell response. Activation of amoxicillin-modified-KP2 or KP3 peptide-specific T-cell clones 
with (A) the amoxicillin dimer-modified KP2 peptide, (C) the ampicillin-modified KP2 peptide 
and (D) the amoxicillin-modified peptide derived from HSA-K204 with similar anchor positions 
to KP3. Clones were incubated with or without the peptides and antigen presenting cells for 
48h. Proliferative responses were measured using [3H]thymidine and recorded as mean ± SD 
cpm of triplicate cultures. (B) Peptide binding competition assay. Amoxicillin-modified 
peptide specific T-cell clones were cultured with the amoxicillin-modified peptides (10µM) in 
the presence of increasing concentration of unmodified peptide for 48h. Proliferative 
responses were measured using [3H]thymidine and recorded as mean ± SD cpm of triplicate 
cultures.
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